MARKET NEWS

Biogen & MedRhythms to Develop & Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
Novartis' Kymriah Receives EC Approval as First CAR-T Cell Therapy for Adults With Relapsed or Refractory Follicular Lymphoma
Compass Therapeutics Reports Positive Interim Phase 2 Data
EyePoint Pharmaceuticals Announces Expanded License Agreement With Betta Pharmaceuticals 
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients With Alzheimer’s Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

Backed by over 90 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

Video Spotlight: Alcami Cleanroom Services

  EXCLUSIVE ONLINE CONTENT

A New Era of Manufacturing: SCHOTT Announces Double-Digit Million Euro Investment in Ready-to-Use Cartridge Production

A New Era of Manufacturing: SCHOTT Announces Double-Digit Million Euro Investment in Ready-to-Use Cartridge Production

The international technology group SCHOTT plans to significantly expand its production capacity of ready-to-use (RTU) cartridges. This drug containment and delivery solution is used….

Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics

Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics

Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on global net sales of products….

Adial Pharmaceuticals Announces Research Collaboration With UC San Diego

Adial Pharmaceuticals Announces Research Collaboration With UC San Diego

Adial Pharmaceuticals, Inc. recently announced Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major….

Owen Mumford & Stevanato Group Sign Exclusive Collaboration Agreement for the Innovative Aidaptus Auto-Injector

Owen Mumford & Stevanato Group Sign Exclusive Collaboration Agreement for the Innovative Aidaptus Auto-Injector

Owen Mumford Ltd recently signed an exclusive agreement that makes Stevanato Group an exclusive manufacturing partner for the Owen Mumford designed auto-injector, offering a full set of capabilities to its….

Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products

Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products

Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical development, has launched Apisolex, a novel solubility-enhancing excipient for use in….

  WHITEPAPERS & WEBINARS

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles can …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 18 – Nasal Drug Delivery
May 25 – Lyophilization Technology